Codexis Q3 product rev $11.2M, net loss narrows to $20.6M; cash $90.3M

CODEXIS, INC.

2024-Q3 EPS reported -$0.78 revenue$37,885,000

Total revenues $12.8M vs $9.3M YoY; product rev $11.2M vs $5.4M; R&D rev $1.7M vs $3.9M.
Net loss $20.6M ($0.29/sh) vs $34.9M ($0.50/sh) YoY; product gross margin 61% vs 58%.
Raised $31M via ATM in Oct 2024; cash $90.3M, expects to fund operations into 2027.
Appointed Georgia Erbez CFO and Alison Moore new CTO (former Allogene CTO).
Licensed genomics enzyme portfolio to Alphazyme/Maravai; eligible for sales-based royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.